International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-5 doi: 10.5281/zenodo.10003252
Original Article
Role of Pcnl in the Management of Horse Shoe Kidney Calculi: 10 Years Study
 ,
 ,
 ,
 ,
 ,
Published
Oct. 14, 2023
Abstract

Introduction: Horse shoe kidney (HSK) is considered as the most common fusion anomaly with an incidence of 1 in 400-666 births. According to AUA and EAU guidelines, PCNL is the surgical modality of choice for renal calculi more than 2 cms even in case of HSK. In this case series, we describe our experience with prone PCNL in the management of nephrolithiasis in HSK over the last 10 years.

Methods: Retrospective analysis of hospital records yielded data of 22 patients who underwent prone PCNL for HSK calculi between June 2012 and May 2022. Patient characteristics and stone characteristics were recorded. Procedure related outcomes like number of tracts established, total procedural time, need for auxiliary procedures, stone free rate and postoperative complications according to modified Clavien Dindo classification were tabulated and analyzed.

Results: Mean age of patients in this study was 44.2 years ranging from 9 to 70 years. Mean stone surface area was 376.54 mm2. Single subcostal upper pole calyceal puncture and tract was able to clear the calculi in 18 cases. Supracostal punctures were required for 4 patients. Auxiliary procedures like redo-PCNL and ESWL were needed in 1 and 2 patients respectively. Blood transfusion was done in 2 patients. Primary stone free rate of82.7% and final stone free rate of 95.5% was achieved.

Conclusion: Prone PCNL is equally safe and efficient management strategy for the treatment of calculi in horse shoe kidneys comparable to PCNL in normal kidneys.

Recommended Articles
Loading Image...
Volume-4, Issue-5
Citations
2365 Views
320 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved